- Home
- COLL vs RNP Comparison
COLL vs RNP Comparison
Compare COLL & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- RNP
- Stock Information
- Founded
- COLL 2002
- RNP 2003
- Country
- COLL United States
- RNP United States
- Employees
- COLL N/A
- RNP N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- RNP Investment Managers
- Sector
- COLL Health Care
- RNP Finance
- Exchange
- COLL Nasdaq
- RNP Nasdaq
- Market Cap
- COLL 958.8M
- RNP 1.1B
- IPO Year
- COLL 2015
- RNP N/A
- Fundamental
- Price
- COLL $32.10
- RNP $21.40
- Analyst Decision
- COLL Strong Buy
- RNP
- Analyst Count
- COLL 4
- RNP 0
- Target Price
- COLL $44.25
- RNP N/A
- AVG Volume (30 Days)
- COLL 354.8K
- RNP 117.6K
- Earning Date
- COLL 11-06-2025
- RNP 01-01-0001
- Dividend Yield
- COLL N/A
- RNP 7.94%
- EPS Growth
- COLL N/A
- RNP N/A
- EPS
- COLL 1.06
- RNP N/A
- Revenue
- COLL $707,007,000.00
- RNP N/A
- Revenue This Year
- COLL $22.23
- RNP N/A
- Revenue Next Year
- COLL $2.78
- RNP N/A
- P/E Ratio
- COLL $31.21
- RNP N/A
- Revenue Growth
- COLL 22.61
- RNP N/A
- 52 Week Low
- COLL $23.23
- RNP $15.52
- 52 Week High
- COLL $39.95
- RNP $21.27
- Technical
- Relative Strength Index (RSI)
- COLL 30.71
- RNP 31.91
- Support Level
- COLL $34.19
- RNP $22.28
- Resistance Level
- COLL $35.83
- RNP $22.58
- Average True Range (ATR)
- COLL 1.05
- RNP 0.25
- MACD
- COLL -0.33
- RNP -0.09
- Stochastic Oscillator
- COLL 0.00
- RNP 11.46
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.